Author: Li, Xinyu; Huang, Lei; Gao, Weijie
Title: Overexpression of Tripartite Motif Conaining 55 (TRIM55) Inhibits Migration and Invasion of Hepatocellular Carcinoma (HCC) Cells via Epithelial-Mesenchymal Transition and Matrix Metalloproteinase-2 (MMP2) Document date: 2019_1_27
ID: 037d5r9i_15
Snippet: Total proteins in HCC cells were extracted by lysis buffer, and the protein concentration was measured by Bicinchoninic acid (BCA) assay. The SDS-PAGE was conducted according to the manufacturer's protocol. After transfer to a PVDF membrane, membranes were incubated with primary antibodies at 4°C overnight in a buffer containing 5% skim milk. The primary antibodies were as follows: TRIM55 (Novus, NBP2-33691, dilution 1/1000), E-cadherin and Vime.....
Document: Total proteins in HCC cells were extracted by lysis buffer, and the protein concentration was measured by Bicinchoninic acid (BCA) assay. The SDS-PAGE was conducted according to the manufacturer's protocol. After transfer to a PVDF membrane, membranes were incubated with primary antibodies at 4°C overnight in a buffer containing 5% skim milk. The primary antibodies were as follows: TRIM55 (Novus, NBP2-33691, dilution 1/1000), E-cadherin and Vimentin (Cell Signaling Technology, (EMT) Antibody Sampler Kit #9782, dilution 1/1000), and MMP2 (Proteintech, 10373-2-AP, dilution 1/1000), and the internal control was GAPDH (Abcam Biotechnology, Cambridge, UK, dilution 1/1000). Then incubated secondary antibody at 37°C for 30 min. The proteins were detected by an Odyssey fluorescence scanner (Li-Cor, Lincoln, NE).
Search related documents:
Co phrase search for related documents- lysis buffer and primary antibody: 1, 2, 3, 4, 5, 6, 7, 8, 9
- lysis buffer and protein concentration: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- lysis buffer and PVDF membrane: 1, 2, 3, 4
- lysis buffer and secondary antibody: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- lysis buffer and skim milk: 1, 2, 3, 4
- lysis buffer and total protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- manufacturer protocol and primary antibody: 1, 2
- manufacturer protocol and secondary antibody: 1, 2
- primary antibody and protein concentration: 1, 2, 3, 4, 5, 6, 7
- primary antibody and PVDF membrane: 1, 2, 3, 4
- primary antibody and secondary antibody: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78
- primary antibody and skim milk: 1, 2, 3, 4
- primary antibody and total protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- protein concentration and PVDF membrane: 1, 2, 3, 4, 5, 6, 7, 8, 9
- protein concentration and secondary antibody: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- protein concentration and skim milk: 1, 2, 3
- protein concentration and total protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75
- PVDF membrane and secondary antibody: 1, 2, 3
- PVDF membrane and skim milk: 1, 2
Co phrase search for related documents, hyperlinks ordered by date